SCHEMBL25860571

SCHEMBL25860571

CCCNC(=O)N(CCP)N=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
BLM P54132 2/20 0.51
PMP22 Q01453 2/20 0.51
MEN1 O00255 1/20 0.51
ABCB11 O95342 1/20 0.51
GSR P00390 1/20 0.51
TSHR P16473 1/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 1/20 0.51
KDM4C Q9H3R0 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
ADRA2A P08913 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EPHX1 P07099 1/20 0.32
PDE4A P27815 1/20 0.32
ADRA1A P35348 1/20 0.32
MCL1 Q07820 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19351408 0.87 ALDH1A1 (0.56) ALDH1A1BLMPMP22MEN1ABCB11
SCHEMBL25860611 0.84 ALDH1A1 (0.53) ALDH1A1BLMPMP22MEN1ABCB11
SCHEMBL10005923 0.82 ALDH1A1 (0.77) ALDH1A1BLMPMP22MEN1ABCB11
SCHEMBL19351409 0.75 ALDH1A1 (0.77) ALDH1A1BLMPMP22MEN1ABCB11
SCHEMBL6751990 0.71 ALDH1A1 (0.60) ALDH1A1BLMPMP22MEN1ABCB11
Carmustine SCHEMBL4503 0.68 ALDH1A1 (1.00) ALDH1A1BLMPMP22MEN1ABCB11
SCHEMBL25859798 0.68 ALDH1A1 (0.56) ALDH1A1BLMPMP22MEN1ABCB11
Carmustine SCHEMBL2047318 0.68 ALDH1A1 (1.00) ALDH1A1BLMPMP22MEN1ABCB11
SCHEMBL1526306 0.67 MMP1 (0.39) ALDH1A1BLMPMP22MEN1ABCB11
SCHEMBL20906025 0.67 ALDH1A1 (0.82) ALDH1A1BLMPMP22MEN1ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212202-A1 TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS YALE UNIVERSITY 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212202-A1 TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS MSH2, MGMT, MSH6 ALDH1A1 227/4885BLM 155/4885PMP22 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.